Navigation Links
NW Bio To Present At 15th Annual BIO CEO & Investor Conference
Date:2/11/2013

BETHESDA, MD, Feb. 11, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers , the Company's Chairman and Chief Executive Officer, will be presenting at the 15th Annual BIO CEO and Investor Conference at 4:30 p.m. on Monday, February 11, 2013 at the Waldorf Astoria Hotel in New York City.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

Ms. Powers' presentation will provide updates about the Company's Phase III and Phase I/II clinical trial programs (including enrollment periods), the Company's operations in Europe, and the Company's plans for 2013.  The presentation will also include recent developments supportive of the approach taken in the Company's DCVax® platform technology.   

The presentation will take place in the East Foyer Meeting Hall and will be available by web cast at http://www.veracast.com/webcasts/bio/ceoinvestor2013/11124539.cfm at approximately 6:00 p.m., one hour following completion of the actual presentation.  It will also available on the NW Bio Website starting on Tuesday morning, February 12, 2013, at www.nwbio.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis,
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vasomedical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
2. Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
3. Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
5. TorkLaw Responds to FDA Warning Letter to St. Jude Medical Regarding Defective Heart Device; Now Representing Patients in 15 States
6. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
7. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
8. Soligenix to Present at 15th Annual BIO CEO & Investor Conference
9. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
10. Ohr Pharmaceutical to Present at 15th Annual BIO CEO & Investor Conference
11. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- The management team at Columbia Laboratories, Inc. (Nasdaq: ... call on July 31, 2014, to discuss financial ... 2014.  The call details are as follows:Date: , ... numbers: , Toll free: (877) 870-4263 (U.S.), (855) ... , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... SUNNYVALE, Calif. , July 23, 2014 /PRNewswire/ ... devices for the transcarotid treatment of intra- and ... Michael P. Wallace to the position ... Michael will lead the company,s Research and Development ... treatment devices. Prior to joining ...
(Date:7/23/2014)... July 23, 2014  Dompe, a leader in R&D for ... that rhNGF (Recombinant Human Nerve Growth Factor) has been designated ... Administration (FDA). The candidate drug, developed by ... drug for the treatment of neurotrophic keratitis, a degenerative corneal ... and is currently without a cure. This is the ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4
... DIEGO, April 20, 2012 /PRNewswire-iReach/ -- Nutrilys ... San Diego, has partnered with the Los Angeles Police ... armor. Nutrilys Del Mar founder, Thierry Lerond, journeyed to Los ... while helping them handpick the world,s best organic, ...
... 2012  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, today announced that ... quarter of fiscal year 2012 on Tuesday, May 1. ... to discuss its financial results and operating activities, open ...
Cached Medicine Technology:Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit 2Thoratec Schedules First Quarter Conference Call, Webcast 2
(Date:7/23/2014)... TX (PRWEB) July 23, 2014 Texas ... seven physical therapists from their Westlake, Westgate, Liberty Hill, ... earned the professional designation of Orthopaedic Certified Specialist ... this June. Adriana Juarez, PT, DPT, OCS, Tony Lauretta, ... Milligan, PT, DPT, OCS, Joseph Leech, PT, DPT, OCS, ...
(Date:7/23/2014)... July 23, 2014 CarePoint Health is ... hospital in New Jersey to receive the da Vinci® ... platform in the da Vinci series. This 4th generation ... step forward in innovation. The intuitive da Vinci Xi ... wide spectrum of minimally invasive and complex surgical procedures. ...
(Date:7/23/2014)... July 23, 2014 Recently, Agebc.com has ... Now, the company is announcing a promotion of wedding ... promotion will end at the end of this month. ... many popular styles, like A-line, mermaid, ball-gown, empire, and ... dresses and other special-occasion dresses for women, and the ...
(Date:7/23/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is focusing on a topic that is quickly ... dialogues: opiate abuse facts. , The Best Drug Rehabilitation blog ... An overview of opiates, and why they’re considered “the mother ...
(Date:7/23/2014)... Europe Drilling fluid and Completion fluid Market Report defines and ... with analysis and forecast of revenue. The drilling fluid and ... around $1.3 billion in 2013 to $1.7 billion by 2018, ... Browse through the TOC of the Europe drilling fluid and ... in-depth analysis provided. This also provides a glimpse of the ...
Breaking Medicine News(10 mins):Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 6
... is widely accepted that urgent endoscopy for UGIB should be performed ... time, it is still unclear whether it should be performed either ... more delayed interval, such as after 6, 12 or 24 hour. ... been yet established. , A research article to be published on ...
... Brazos Valley residents,neuroscience researchers, and interested clinicians will ... on the,topic of stroke during the Texas Brain ... 19. This year,s symposium will consist of a,morning ... for clinicians,and researchers. The speakers are both neuroscience ...
... Dialysis Providers, Patient Advocates Work with Local Kidney,Community ... Texas, Sept. 9 With the,highest per capita ... the,Gulf Coast region is bracing to avoid a ... disrupt the administration of,life-saving dialysis treatments to area ...
... 9 Encorium Group, Inc.,(Nasdaq: ENCO ), ... studies in over 30 countries for many of ... that it,has entered into an amendment (the "Amendment") ... Inc. ("Prologue"). Pursuant to the,Amendment, the Company will ...
... Correction of Familial Risk Estimates Increases Estimated Melanoma Risk ... The relative risk of familial melanoma increases substantially when ... large cohort study. The relative risk of familial lung, ... with the correction. , Researchers have used the Swedish ...
... in the United States undergo lung surgery each year, ... their care. In the current issue of The ... proposed a system of lung surgery quality indicators for ... best practices for obtaining positive patient outcomes. , Death ...
Cached Medicine News:Health News:Texas Brain and Spine Institute to Hold Second Annual Neuroscience Symposium 2Health News:Gulf Coast Dialysis Caregivers, Volunteers Brace for Hurricane Ike; Prepare to Maintain Power, Continued Access for Patients to Life-Saving Treatment 2Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 2Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 3Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 4Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 5Health News:Also in the Sept. 9 JNCI 2Health News:Also in the Sept. 9 JNCI 3Health News:Mayo Clinic chest surgeons propose measures for indicating quality of lung surgery 2Health News:Mayo Clinic chest surgeons propose measures for indicating quality of lung surgery 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: